NCT04201561 - High Dose Inorganic Selenium for Preventing Chemotherapy Induced Peripheral Neuropathy | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 24, 2019

Primary Completion Date

April 30, 2023

Study Completion Date

December 31, 2024

Conditions

Chemotherapy-induced Peripheral NeuropathyRecurrent Ovarian CarcinomaOvarian CancerFallopian Tube CancerPrimary Peritoneal Carcinoma

Interventions

DRUG

sodium selenite pentahydrate

High-dose inorganic selenium (2000 μg/40 ml) will be administered before chemotherapy in patients assigned to the experimental group.

DRUG

Normal saline

Normal saline (40 ml) will be administered before chemotherapy in patients assigned to the control group.

DRUG

Chemotherapy

Paclitaxel (175mg/m2), carboplatin (AUC 5.0 or 6.0) IV, and bevacizumab IV (15mg/kg) D1, every three weeks.

Trial Locations (1)

Seoul National University Hospital, Seoul